Osteoarthritis Pain – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Osteoarthritis Pain – Pipeline Review, H2 2019’, provides an overview of the Osteoarthritis Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoarthritis Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain

– The report reviews pipeline therapeutics for Osteoarthritis Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Osteoarthritis Pain therapeutics and enlists all their major and minor projects

– The report assesses Osteoarthritis Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Osteoarthritis Pain”

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AbbVie Inc

Achelios Therapeutics Inc

AKL Research and Development Ltd

Ampio Pharmaceuticals Inc

Andros Pharmaceuticals Co Ltd

AntalGenics SL

Antibe Therapeutics Inc

Apimeds Inc

Aquilus Pharmaceuticals Inc

Arena Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Axsome Therapeutics Inc

Calchan Ltd

Cara Therapeutics Inc

CDA Research Group Inc

Centrexion Therapeutics Corp

Chromocell Corp

Cmxtwenty

Concentric Analgesics Inc

Elite Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc

Flexion Therapeutics Inc

Futura Medical Plc

GlaxoSmithKline Plc

Grunenthal GmbH

Hisamitsu Pharmaceutical Co Inc

Ichnos Sciences Inc

Iroko Pharmaceuticals LLC

Levicept Ltd

Mestex AG

Nuvo Pharmaceuticals Inc

Olatec Therapeutics LLC

OliPass Corporation

Ono Pharmaceutical Co Ltd

Peptide Logic LLC

Pfizer Inc

Pharmnovo AB

ProteoThera Inc

RaQualia Pharma Inc

Regeneron Pharmaceuticals Inc

Rottapharm Biotech Srl

Sansho Co Ltd

Shionogi & Co Ltd

Shulov Innovative Science Ltd

Sorrento Therapeutics Inc

Symic Bio Inc

Taiwan Liposome Co Ltd

Techfields Pharma Co Ltd

Vertex Pharmaceuticals Inc

Xalud Therapeutics Inc

Xenexus Pharmaceuticals Pty Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Osteoarthritis Pain - Overview 6

Osteoarthritis Pain - Therapeutics Development 7

Osteoarthritis Pain - Therapeutics Assessment 18

Osteoarthritis Pain - Companies Involved in Therapeutics Development 28

Osteoarthritis Pain - Drug Profiles 46

Osteoarthritis Pain - Dormant Projects 201

Osteoarthritis Pain - Discontinued Products 205

Osteoarthritis Pain - Product Development Milestones 207

Appendix 216

List of Tables

“List of Tables

Number of Products under Development for Osteoarthritis Pain, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Osteoarthritis Pain – Dormant Projects, H2 2019

Osteoarthritis Pain – Dormant Projects, H2 2019 (Contd..1), H2 2019

Osteoarthritis Pain – Dormant Projects, H2 2019 (Contd..2), H2 2019

Osteoarthritis Pain – Dormant Projects, H2 2019 (Contd..3), H2 2019

Osteoarthritis Pain – Dormant Projects, H2 2019 (Contd..4), H2 2019

Osteoarthritis Pain – Discontinued Products, H2 2019

Osteoarthritis Pain – Discontinued Products, H2 2019 (Contd..1), H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports